<DOC>
	<DOCNO>NCT01395758</DOCNO>
	<brief_summary>The purpose study evaluate progression-free survival among subject KRAS mutation positive Non-Small Cell Lung Cancer ( NSCLC ) treat erlotinib plus tivantinib ( ARQ 197 ) compare single agent chemotherapy .</brief_summary>
	<brief_title>Erlotinib Plus Tivantinib ( ARQ 197 ) Versus Single Agent Chemotherapy Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This randomize , open-label Phase 2 study design compare treatment erlotinib plus tivantinib ( ARQ 197 ) versus single agent chemotherapy subject previously treat KRAS mutation positive NSCLC . Eligible subject randomly assign receive erlotinib plus tivantinib one three ( base Investigator 's decision ) single-agent chemotherapy agent include pemetrexed , docetaxel , gemcitabine .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Provide sign date informed consent prior studyspecific screening procedure 2 . Male female least 18 year age 3 . Histologically cytologically confirm inoperable locally advanced metastatic ( stage IVA/IVB ) NSCLC 4 . Documented KRAS mutation positive status ( per LCMC guideline ; see www.golcmc.com ) 5 . At least one prior chemotherapy regimen advance NSCLC 6 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , Version 1.1 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 8 . Male female subject childproducing potential must agree use double barrier contraception , oral contraceptive avoidance pregnancy measure study 90 day last day treatment 9 . Females childbearing potential must negative serum pregnancy test 10 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) ≤ 5 × ULN metastatic liver disease 11 . Total bilirubin ≤ 1.5 × ULN 12 . Serum creatinine ≤ 1.5 × ULN 13 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L 14 . Platelets ≥ 100 x 10^9/L 15 . Hemoglobin ≥ 10 g/dL ( transfusion allow least 7 day prior randomization ) 16 . Subjects must agree allow test cMet status archival and/or fresh tissue biopsy sample available . 1 . Previous receipt erlotinib EGFR 2 . Previous receipt cMET inhibitor cMETtargeted therapy , include ARQ 197 , MetMab , crizotinib 3 . Prior receipt chemotherapy agent select administration study ( e.g. , subject treat gemcitabine , eligible receive gemcitabine study eligible receive pemetrexed docetaxel ) . 4 . Inability unwillingness receive ARQ 197 , erlotinib , docetaxel , gemcitabine , and/or pemetrexed include contraindication , hypersensitivity , prior administration 5 . Receipt antitumor treatment NSCLC within 3 week ( 2 week radiotherapy ) prior randomization 6 . Pregnant breastfeed 7 . Significant gastrointestinal disorder could , opinion Investigator , interfere absorption ARQ 197 and/or erlotinib 8 . Any significant comorbid condition opinion Investigator would impair study participation cooperation 9 . Other malignancy within last three year , exception adequately treat intraepithelial carcinoma cervix uterus , prostate carcinoma PSA value &lt; 0.2 ng/mL basal squamous cell carcinoma skin 10 . Known human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection 11 . Major surgical procedure within 4 week prior randomization 12 . History cardiac disease : Congestive heart failure define Class II IV per New York Heart Association classification ; Active coronary artery disease ; Previously diagnose bradycardia cardiac arrhythmia define ≥ Grade 2 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 , uncontrolled hypertension ; Myocardial infarction occur within 6 month prior study entry ( myocardial infarction occur &gt; 6 month prior study entry permit ) 13 . Clinically unstable central nervous system metastasis ( enrol study , subject must confirmation stable disease MRI CT scan within 4 week randomization CNS metastases well controlled steroid , antiepileptic symptomrelieving medication ) 14 . Known EGFRmutation positive status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>KRAS mutation</keyword>
	<keyword>metastatic NSCLC</keyword>
</DOC>